BPC-157Anticoagulants
Caution / monitorAnticoagulants & bleeding
Theoretical synergy via NO modulation — monitor.
BPC-157VEGF inhibitors
Avoid / antagonisticOncology & growth signaling
Mechanistic opposition; avoid combination.
MOTS-cMetformin
InformationalGlucose & diabetes meds
Both activate AMPK — stacking effect unclear.
MOTS-cSGLT2 inhibitors
InformationalGlucose & diabetes meds
Potential additive glucose-lowering.
Additive effects on pineal signaling.
Mechanistic overlap; effect unclear.
CJC-1295Insulin
Caution / monitorGlucose & diabetes meds
GH antagonizes insulin; monitor glucose.
CJC-1295Corticosteroids
Caution / monitorHormonal & GH axis
Blunt GH response.
IpamorelinGHRH analogues (CJC-1295)
InformationalHormonal & GH axis
Synergistic GH release.
IpamorelinSomatostatin analogues
Avoid / antagonisticHormonal & GH axis
Antagonistic — avoid combination.
DihexaTyrosine kinase modulators
InformationalOncology & growth signaling
Mechanistic overlap with c-Met signaling.
PinealonOther bioregulator peptides
InformationalOther peptides & stacks
Often stacked; interactions not characterized.
TB-500Anticoagulants
Caution / monitorAnticoagulants & bleeding
Theoretical effect on tissue remodeling — caution.
TB-500BPC-157
InformationalOther peptides & stacks
Frequently co-stacked; no formal interaction studies.
Mechanistically distinct but caution if combined.
RetatrutideInsulin and sulfonylureas
Caution / monitorGlucose & diabetes meds
Risk of hypoglycemia — dose reduction usually required.
RetatrutideOral medications
Caution / monitorOral drug absorption
Delayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.
Interaction categories and severities are inferred from published notes and are not a substitute for a clinician review. Absence of a listed interaction is not evidence of safety — always cross-reference for any drug you take.